New treatment approaches in juvenile idiopathic arthritis

International Journal of Advances in Rheumatology

Volumn 7, Issue 1, 2009, Pages 1-9

  Holzinger, Dirk ^a   Frosch, Michael ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955309369     PISSN: 1478856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Petty RE, Southwood TR. Classification of childhood arthritis: divide and conquer. J Rheumatol 1998;25:1869-70. (Pubitemid 28459296)
2. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-78.
3. Berntson L, Andersson Gäre B, Fasth A et al. Incidence of juvenile idiopathic arthritis in the Nordic countries. A population based study with special reference to the validity of the ILAR and EULAR criteria. J Rheumatol 2003;30:2275-82. (Pubitemid 37221864)
4. Manners PJ, Bower C. Worldwide prevalence of juvenile arthritis why does it vary so much? J Rheumatol 2002;29:1520-30. (Pubitemid 34755622)
5. Glass DN, Giannini EH. Juvenile rheumatoid arthritis as a complex genetic trait. Arthritis Rheum 1999;42:2261-8. (Pubitemid 30333403)
6. Prahalad S. Genetics of juvenile idiopathic arthritis: an update. Curr Opin Rheumatol 2004;16:588-94. (Pubitemid 39128329)
7. Thomson W, Donn R. Juvenile idiopathic arthritis genetics - what's new? What's next? Arthritis Res 2002;4:302-6. (Pubitemid 34947144)
8. Rosen P, Thompson S, Glass D. Non-HLA gene polymorphisms in juvenile rheumatoid arthritis. Clin Exp Rheumatol 2003;21:650-6. (Pubitemid 37236463)
9. Fishman D, Faulds G, Jeffery R et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998;102:1369-76. (Pubitemid 28467565)
10. Ogilvie EM, Fife MS, Thompson SD et al. The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum 2003;48:3202-6. (Pubitemid 37409332)
11. Gregorio A, Gambini C, Gerloni V et al. Lymphoid neogenesis in juvenile idiopathic arthritis correlates with ANA positivity and plasma cells infiltration. Rheumatology (Oxford) 2007;46:308-13. (Pubitemid 46189794)
12. Murray KJ, Luyrink L, Grom AA et al. Immunohistological characteristics of T cell infiltrates in different forms of childhood onset chronic arthritis. J Rheumatol 1996;23:2116-24. (Pubitemid 27006760)
13. Scola MP, Imagawa T, Boivin GP et al. Expression of angiogenic factors in juvenile rheumatoid arthritis: correlation with revascularization of human synovium engrafted into SCID mice. Arthritis Rheum 2001;44:794-801. (Pubitemid 32319771)
14. Gattorno M, Gerloni V, Morando A et al. Synovial membrane expression of matrix metalloproteinases and tissue inhibitor 1 in juvenile idiopathic arthritides. J Rheumatol 2002;29:1774-9. (Pubitemid 34831255)
15. De Benedetti F, Pignatti P, Gerloni V et al. Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J Rheumatol 1997;24:1403-9. (Pubitemid 27353389)
16. De Benedetti F, Martini A. Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis? Arthritis Rheum 2005;52:687-93. (Pubitemid 40365088)
17. Pascual V, Allantaz F, Arce E et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-86. (Pubitemid 40664091)
18. Hashkes PJ, Laxer RM. Medical treatment of juvenile idiopathic arthritis. JAMA 2005;294:1671-84. (Pubitemid 41407360)
19. Ilowite NT. Current treatment of juvenile rheumatoid arthritis. Pediatrics 2002;109:109-15. (Pubitemid 34049434)
20. Ravelli A, Martini A. Methotrexate in juvenile idiopathic arthritis: answers and questions. J Rheumatol 2000;27:1830-3. (Pubitemid 30670474)
21. Ruperto N, Murray KJ, Gerloni V et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004;50:2191-201. (Pubitemid 38924397)
22. Silverman E, Mouy R, Spiegel L et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005;352:1655-66. (Pubitemid 40530232)
23. Wallace CA. The use of methotrexate in childhood rheumatic diseases. Arthritis Rheum 1998;41:381-91. (Pubitemid 28128761)
24. Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2008;47:249-55. (Pubitemid 351267187)
25. Silverman E, Spiegel L, Hawkins D et al. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2005;52:554-62. (Pubitemid 40216320)
26. Wallace CA. On beyond methotrexate treatment of severe juvenile rheumatoid arthritis. Clin Exp Rheumatol 1999;17:499-504. (Pubitemid 29343640)
27. Prince FH, Twilt M, Jansen-Wijngaarden NC et al. Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study. Ann Rheum Dis 2007;66:704-5. (Pubitemid 46707146)
28. Kuemmerle-Deschner JB, Horneff G. Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis. Rheumatol Int 2007;28:153-6. (Pubitemid 350105867)
29. Horneff G, Schmeling H, Biedermann T et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1638-44. (Pubitemid 39573695)
30. Lovell DJ, Giannini EH, Reiff A et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9. (Pubitemid 30151920)
31. Lovell DJ, Reiff A, Ilowite NT et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-504. (Pubitemid 351705939)
32. Lovell DJ, Reiff A, Jones OY et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006;54:1987-94. (Pubitemid 43877949)
33. Robinson RF, Nahata MC, Hayes JR et al. Quality-of-life measurements in juvenile rheumatoid arthritis patients treated with etanercept. Clin Drug Investig 2003;23:511-8. (Pubitemid 37041007)
34. Lovell DJ, Ruperto N, Goodman S et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20.
35. Ruperto N, Lovell DJ, Quartier P et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:383-91.
36. Levalampi T, Honkanen V, Lahdenne P et al. Effects of infliximab on cytokines, myeloperoxidase, and soluble adhesion molecules in patients with juvenile idiopathic arthritis. Scand J Rheumatol 2007;36:189-93. (Pubitemid 47174546)
37. Gerloni V, Pontikaki I, Gattinara M et al. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum 2005;52:548-53. (Pubitemid 40216319)
38. Ruperto N, Lovell DJ, Cuttica R et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007;56:3096-106. (Pubitemid 47502757)
39. Ruperto N, Lovell DJ, Cuttica R et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 2009; [Epub ahead of print].
40. Ohlsson V, Baildam E, Foster H et al. Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology (Oxford) 2008;47:555-6.
41. Irigoyen P, Olsen J, Hom C et al. Treatment of systemic juvenile rheumatoid arthritis with anakinra. Arthritis Rheum 2004;50(Suppl.):S437.
42. Verbsky JW, White AJ. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004;31:2071-5. (Pubitemid 39336738)
43. Lequerre T, Quartier P, Rosellini D et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis 2008;67:302-8. (Pubitemid 351281262)
44. Quartier P, Allantaz F, Cimaz R et al. Anakinra in systemic-onset juvenile idiopathic arthritis: results of a multicenter double-blind trial. Ann Rheum Dis 2008;67(Suppl II):68.
45. Ilowite N, Porras O, Reiff A et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009;28:129-37.
46. Lovell DJ, Giannini EH, Kimura Y. Preliminary evidence for sustained bioactivity of IL-1 Trap (rilonacept), a long acting IL-1 inhibitor, in systemic juvenile idiopathic arthritis (sJIA). Arthritis Rheum 2007;56:514.
47. Church LD, McDermott MF. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther 2009;11:81-9.
48. Yokota S, Miyamae T, Imagawa T et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005;52:818-25. (Pubitemid 40365104)
49. Yokota S, Imagawa T, Mori M et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal Phase III trial. Lancet 2008;371:998-1006. (Pubitemid 351389534)
50. Yokota S, Imagawa T, Miyamae T et al. Long-term safety and efficacy of tocilizumab in patients with systemic juvenile idiopathic arthritis (JIA) under the extension and long-term trials. Program and abstracts of the American College of Rheumatology (ACR) 2008 Annual Scientific Meeting; October 24-29, 2008; San Francisco, CA, USA. Abstract 1244.
51. Narváez J, Díaz-Torné C, Juanola X et al. Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 2009;68:607-8.
52. Kuek A, Hazleman BL, Gaston JH et al. Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab. Rheumatology (Oxford) 2006;45:1448-9. (Pubitemid 44605487)
53. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16. (Pubitemid 32224400)
54. Mangge H, Kenzian H, Gallistl S et al. Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes. Arthritis Rheum 1995;38:211-20.
55. Bresnihan B, Alvaro-Gracia JM, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204. (Pubitemid 29009378)
56. Goldbach-Mansky R, Shroff SD, Wilson M et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008;58:2432-42.
57. Hoffman HM, Throne ML, Amar NJ et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008;58:2443-52.
58. De Benedetti F, Massa M, Pignatti P et al. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 1994;93:2114-9.
59. de Benedetti F, Massa M, Robbioni P et al. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1991;34:1158-63.
60. Cazzola M, Ponchio L, de Benedetti F et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemiconset juvenile chronic arthritis. Blood 1996;87:4824-30. (Pubitemid 26162385)
61. + regulatory T cells in inflamed synovia. J Exp Med 2005;201:1793-803.
62. bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol 2004;172:6435-43.
63. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81. (Pubitemid 38758544)